These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30192155)

  • 1. Costs associated with adverse events for systemic therapies in metastatic melanoma.
    Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
    J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden associated with adverse events in patients with metastatic melanoma.
    Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
    J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
    Gorry C; McCullagh L; Barry M
    Value Health; 2020 Jan; 23(1):52-60. PubMed ID: 31952674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
    Ghate SR; Li Z; Tang J; Nakasato AR
    Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
    Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
    Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
    Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
    Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
    Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
    Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
    Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
    J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
    Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
    Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
    Ma Q; Zhao Z; Barber BL; Shilkrut M
    Adv Ther; 2016 Feb; 33(2):282-9. PubMed ID: 26797898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.